LEADER 03055nam 2200421z- 450 001 9910137094503321 005 20231214132852.0 035 $a(CKB)3710000000824719 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/53904 035 $a(EXLCZ)993710000000824719 100 $a20202102d2015 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aMonitoring endogenous GPCRs: lessons for drug design 210 $cFrontiers Media SA$d2015 215 $a1 electronic resource (134 p.) 225 1 $aFrontiers Research Topics 311 $a2-88919-651-8 330 $aG protein-coupled receptors (GPCRs) are integral membrane proteins forming the fourth largest superfamily in the human genome. Many of these receptors play key physiological roles and several pathologies have been associated with receptor functional abnormalities. GPCRs therefore represent important goals for drug design in pharmaceutical companies since they constitute the target of about one third of the drugs currently on the market. However, endogenous GPCRs are most often difficult to study because of a lack of tools to target them specifically and single out their response to physiological or drug-elicited stimulations. Hence, studies mostly focused on recombinant receptors expressed in a variety of cellular models that do not always closely reflect the receptor natural environment and often deal with levels of expression exceeding by far physiological ranges. Recent technological developments combining for example genetically modified animals and advanced imaging approaches have improved our ability to visualize endogenous GPCRs. To date, trailing receptor activation, subsequent intracellular redistribution, changes in signaling cascade up to integrated response to a drug-elicited stimulation is at hand though the impact of a physiological challenge on receptor dynamics remains a major issue. Data however suggest that the receptor may embrace a different fate depending on the type of stimulation in particular if sustained or repeated. This suggests that current drugs may only partially mimic the genuine response of the receptor and may explain, at least in part, their secondary effects. Commonalities and specificities between physiological and drug-induced activation can thus represent valuable guidelines for the design of future drugs. 517 $aMonitoring endogenous GPCRs 610 $aopioid receptors 610 $aG protein coupled receptors 610 $aCGamP mice 610 $aFLIM 610 $afluorescent knock-in mice 610 $areceptor heteromerization 610 $aEndogenous receptors 610 $acannabinoid receptors 610 $abiased signaling 610 $aOpiate tolerance 700 $aDominique Massotte$4auth$01305913 906 $aBOOK 912 $a9910137094503321 996 $aMonitoring endogenous GPCRs: lessons for drug design$93028010 997 $aUNINA